ArticlePsycho-oncology2017
Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer.
Article in Psycho-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence of cognitive impairment and change in patients with breast cancer: A systematic review of longitudinal studies.Psycho-oncology · 2021Pooled it
- Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment.Journal of cancer survivorship : research and practice · 2018Pooled it
- Worry and Mindfulness Differentially Impact Symptom Burden Following Treatment Among Breast Cancer Survivors: Findings From a Randomized Crossover Trial.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2023Trial
- Effects of Vigorous Versus Restorative Yoga Practice on Objective Cognition Functions in Sedentary Breast and Ovarian Cancer Survivors: A Randomized Controlled Pilot Trial.Integrative cancer therapiesTrial
- Chemotherapy-Induced Skeletal Muscle Dysfunction and Cognitive Impairment: A Muscle-Brain Mechanistic Framework With Implications for Exercise Oncology.Journal of cachexia, sarcopenia and muscle · 2026Review
- Role function in postmenopausal women during aromatase inhibitor therapy for breast cancer.Journal of cancer survivorship : research and practice · 2026Article
- Symptom Clusters in Brazilian Women With Stage I and Stage III Nonmetastatic Breast Cancer: A Cross-Sectional Study.The breast journal · 2026Article
- Longitudinal assessment of cognitive function in patients with breast cancer and lymphoma receiving chemotherapy.JNCI cancer spectrum · 2025Article
- DNA methylation associations with cognitive function in early-stage hormone receptor-positive breast cancer patients.Epigenomics · 2025Article
- Characterizing cancer-related cognitive impairments and impact on quality of life in women with metastatic breast cancer.Breast cancer research and treatment · 2025Article
- Impact of menopausal status on cognitive function in female papillary thyroid carcinoma patients: a longitudinal propensity score matched study.BMC women's health · 2024Article
- You can't spell distress without stress: Expanding our perspective of the intersection between mental and physical health in cancer survivors.Comprehensive psychoneuroendocrinology · 2024Review
- Memory Impairments and Wellbeing in Breast Cancer Patients: A Systematic Review.Journal of clinical medicine · 2023Review
- Subjective cognition and memory lapses in the daily lives of breast cancer survivors: Examining associations with objective cognitive performance, fatigue, and depressed mood.Psycho-oncology · 2023Article
- Education, incident cancer, and rate of memory decline in a national sample of US adults in mid-to-later-life.Journal of geriatric oncology · 2023Article
- Signal Variability and Cognitive Function in Older Long-Term Survivors of Breast Cancer with Exposure to Chemotherapy: A Prospective Longitudinal Resting-State fMRI Study.Brain sciences · 2022Article
- Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review.Cancers · 2022Review
- Longitudinal Changes in Cognitive Function in a Nationwide Cohort Study of Patients With Lymphoma Treated With Chemotherapy.Journal of the National Cancer Institute · 2022Observational
- Symptom trajectories in patients with breast cancer: An integrative review.International journal of nursing sciences · 2022Review
- Measuring Self-Reported Cancer-Related Cognitive Impairment: Recommendations From the Cancer Neuroscience Initiative Working Group.Journal of the National Cancer Institute · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveIn a sample of 368 postmenopausal women, we (1) determined within-cohort and between-cohort relationships between adjuvant systemic therapy for breast cancer and self-reported cognitive function during the first 18 months of therapy and (2) evaluated the influence of co-occurring symptoms, neuropsychological function, and other covariates on relationships.
methodsWe evaluated self-reported cognitive function, using the Patient Assessment of Own Functioning Inventory (PAOFI), and potential covariates (e.g., co-occurring symptom scores and neuropsychological function z-scores) in 158 women receiving aromatase inhibitor (AI) therapy alone, 104 women receiving chemotherapy followed by AI therapy, and 106 non-cancer controls. Patients were assessed before systemic therapy and then every 6 months, for a total of four assessments over 18 months. Controls were assessed at matched time points. Mixed-effects modeling was used to determine longitudinal relationships.
resultsControlling for covariates, patients enrolled before chemotherapy reported poorer global cognitive function (p < 0.001), memory (p < 0.001), language and communication (p < 0.001), and sensorimotor function (p = 0.002) after chemotherapy. These patients reported poorer higher-level cognitive and intellectual functions from before chemotherapy to 12 months after initiation of AI therapy (p < 0.001). Higher levels of depressive symptoms (p < 0.001), anxiety (p < 0.001), and fatigue (p = 0.040) at enrollment were predictors of poorer cognitive function over time. PAOFI total score was a predictor of executive function (p = 0.048) and visual working memory (p = 0.005) z-scores, controlling for covariates.
conclusionsFindings provide further evidence of poorer self-reported cognitive function after chemotherapy and of relationships between co-occurring symptoms and cognitive changes. AI therapy alone does not have an impact on self-reported cognitive function. Copyright © 2015 John Wiley & Sons, Ltd.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.